Home > News > Targeted and Immune Therapies in Non-small Cell Lung Cancer—Latest Advances
Lung Cancer
Read Time: 2 mins

Targeted and Immune Therapies in Non-small Cell Lung Cancer—Latest Advances

Published Online: November 20th 2017 Oncology & Hematology Review. 2017;13(2):77–8 DOI: https://doi.org/10.17925/OHR.2017.13.02.77
Authors: Suresh S Ramalingham
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

In recent years the treatment landscape of non-small cell lung cancer (NSCLC) has been transformed. The emergence of therapies targeting specific genetic alterations, such as epidermal growth factor (EGFR) mutations, as well as immune checkpoint inhibitors targeting the transmembrane protein programmed death-1 (PD1) and its ligand (PDL1), has increased the therapeutic options for patients with NSCLC. In an expert interview, Suresh S Ramalingam discusses recent advances in targeted and immune therapy and considers the role of chemotherapy within this rapidly evolving therapeutic paradigm.

Keywords

Immune therapies, NSCLC, EGFR mutation, anti-PDL1, pembrolizumab

Article:

Q: Following the emergence of targeted therapies in non-small cell lung cancer, how useful is the testing of circulating tumor-derived DNA for EGFR mutation testing?

Testing peripheral blood for actionable mutations represents a major advance in the management of lung cancer. It is now possible to understand mechanisms of resistance to EGFR-targeted therapies. Recently, the Food and Drug Administration (FDA) approved a plasma based test for detection of EGFR mutation in patients with newly-diagnosed advanced NSCLC as a companion-diagnostic to treatment with erlotinib. In addition, plasma testing for T790M is associated with high sensitivity and specificity, and can also be used to support the use of osimertinib, a T790M inhibitor for patients with acquired resistance to EGFR tyrosine kinase inhibitors. In addition, plasma testing also provides avenues for research on longitudinal monitoring for resistance, and early detection of cancer recurrence.

Q: What do you see as the major challenges in targeted therapy in EGFR mutation positive non-small cell lung cancer?

Every patient treated with an EGFR inhibitor develops acquired resistance. As our understanding of these mechanisms have improved, new targeted therapies such as osimertinib have been developed. It is now possible to administer osimertinib as front-line therapy and avoid the emergence of T790M mechanisms of resistance. The next steps will be to understand potential mechanisms of resistance to third generation EGFR inhibitors and develop strategies to overcome them. In addition, combining third generation EGFR inhibitors with other molecularly targeted agents to extend the benefits to patients with EGFR mutations remains an important priority.

Q: How is emerging data on the anti-PD1 agents changing the treatment paradigm in non-small cell lung cancer?

Checkpoint inhibitors are used now for routine care of patients with advanced stage NSCLC. Monotherapy with checkpoint inhibitors is associated with survival benefit over standard chemotherapy for several agents in the salvage therapy setting. Studies have documented improved survival outcomes with pembrolizumab for patients with high PDL1 expression in the front line treatment of advanced NSCLC. Based on these, the treatment paradigm for advanced stage NSCLC have shifted with incorporation of immune checkpoint inhibition.

Q: What is the current status of the clinical development of anti-PDL1 agents, such as atezolizumab?

Atezolizumab is a PDL1 inhibitor that has been approved for the treatment of salvage therapy of advanced stage NSCLC. It has demonstrated superiority over docetaxel in randomized phase III trials. Atezolizumab is now being studied in combination with chemotherapy for front-line treatment of advanced stage NSCLC. It is also being studied in the adjuvant therapy setting for patients with early stage NSCLC. Combination of atezolizumab with other immunotherapy agents is also an active area of development.

Q: How do you see the role of chemotherapy in non-small cell lung cancer evolving in the areas of targeted therapy and immunotherapy?

Chemotherapy continues to play an important role in the treatment of NSCLC. For patients with PDL1 expression lower than 50%, chemotherapy continues to be the mainstay of treatment. Even for patients with high PDL1 expression who receive immune checkpoint inhibition as monotherapy, upon progression, platinum-based chemotherapy is used. Sequencing chemotherapy with immune checkpoint inhibition and evaluation of combination regimens with immune checkpoint inhibition are all areas of active investigation.

Article Information:
Disclosure

Suresh S Ramalingham has nothing to declare
in relation to this article. No funding was received in the
publication of this article. This is an expert opinion piece
and has not been submitted to external peer reviewers.

Correspondence

Suresh S Ramalingham,
Winship at Emory University Hospital Midtown,
550 Peachtree Street, NE Atlanta, Georgia 30308, US.
E: SSRAMAL@emory.edu

Open Access

This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any noncommercial use, distribution,
adaptation, and reproduction provided the original
author(s) and source are given appropriate credit.

Received

2017-08-30T00:00:00

Further Resources

Share this Article
Related Content In Lung Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72